View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
November 30, 2021

Coronavirus company news summary – Pfizer-BioNTech to seek Covid-19 booster authorisation for 16 to 17-year-olds – Celltrion enters contract with Europe to supply Covid-19 antibody therapy

By Darcy Jimenez

Pfizer and BioNTech are set to seek authorisation from the US Food and Drug Administration for the booster Covid-19 vaccines for usage in individuals aged 16-17 years soon, CNN reported. Currently, booster shots are indicated for use in people aged 18 years and above, six months after the initial dosing regimen. Meanwhile, the US Centers for Disease Control and Prevention has advised all adults to receive booster doses with the emergence of the new SARS-CoV-2 variant Omicron.

Celltrion’s distribution division has entered deals with nine European countries to deliver its monoclonal antibody therapy, Regkirona (regdanvimab, CT-P59), for the treatment of Covid-19. Recently, the European Commission granted marketing authorisation for the drug. Regkirona is intended for use in adult Covid-19 patients who do not need supplemental oxygen but are at high disease progression risk. The initial shipment of 50,000 doses will be made to Europe this year while Celltrion is holding discussions with 47 other countries.

Immunome has filed an Investigational New Drug application with the US Food and Drug Administration to commence clinical trials of its three-antibody cocktail, IMM-BCP-01, to treat Covid-19. Acting on the non-overlapping regions of the Spike protein, IMM-BCP-01 induces multi-modal activity in pre-clinical analysis. In in vitro testing, the antibody combination showed the potential to lower viral load in lungs of Covid-19-infected hamsters and could also neutralise present, as well as former, variants of concern.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology